Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Biochemically Recurrent Prostate Cancer Clear all
Active, not recruiting Phase 2 Interventional

ArtemiCoffee in Patients With Rising PSA

NCT05478239
View directory record Official record
Conditions
Prostate Cancer
Interventions
ArtemiCoffee
Drug
Lead sponsor
Zin W Myint
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jun 10, 2026, 5:15 AM EDT
Active, not recruiting Phase 1 Interventional

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

NCT05617885
View directory record Official record
Conditions
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
Interventions
Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate, GNRH-A Goserelin, Degarelix
Drug
Lead sponsor
Praful Ravi, MB BCHir, MRCP
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 10, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional

Ga-68-PSMA-11 in Men With Prostate Cancer

NCT05744115
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Ga-68-PSMA-11
Drug
Lead sponsor
Timothy Hoffman
Federal
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Jun 10, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy

NCT00779168
View directory record Official record
Conditions
Prostate Cancer
Interventions
white button mushroom extract, flow cytometry, immunologic technique, laboratory biomarker analysis, gas chromatography-mass spectrometry, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jun 10, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.

NCT05946824
View directory record Official record
Conditions
Recurrent Prostate Cancer After Surgery
Interventions
Daily-adaptive Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jun 10, 2026, 5:15 AM EDT
Withdrawn No phase listed Observational

Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly

NCT00161252
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
75 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Jun 10, 2026, 5:15 AM EDT
Active, not recruiting Phase 2 Interventional

Radium-223 in Biochemically Recurrent Prostate Cancer

NCT04206319
View directory record Official record
Conditions
Biochemical Recurrent Prostate Cancer
Interventions
Radium-223, 18F Sodium Fluoride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jun 10, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

NCT04050215
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma, PSA Level Greater Than Fifty, PSA Progression, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Jun 10, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

NCT04523207
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, ADT, Relugolix
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
32
States / cities
Tucson, Arizona • Little Rock, Arkansas • Sherman Oaks, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 10, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Perifosine in Treating Patients With Recurrent Prostate Cancer

NCT00058214
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
perifosine, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Jun 10, 2026, 5:15 AM EDT
Active, not recruiting Phase 2 Interventional

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

NCT04335682
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer, Castrate Resistant Prostate Cancer, Hormone Sensitive Prostate Cancer, Non-metastatic Prostate Cancer
Interventions
Darolutamide, Enzalutamide
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Male only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Fairway, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jun 10, 2026, 5:15 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906
View directory record Official record
Conditions
Biochemically Recurrent Prostate Cancer
Interventions
Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 10, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

NCT04336943
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Durvalumab, Olaparib, Quality-of-Life Assessment, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jun 10, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide

NCT05526248
View directory record Official record
Conditions
Biochemically Recurrent Prostate Cancer
Interventions
Darolutamide(BAY1841788, Nubeqa), Enzalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Sherman Oaks, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jun 10, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer

NCT01341652
View directory record Official record
Conditions
Prostate Cancer
Interventions
pTVG-HP, rhGM-CSF
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jun 10, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

NCT04700332
View directory record Official record
Conditions
Prostate Cancer
Interventions
DCFPyL PET/CT
Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older · Male only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Jun 10, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer

NCT00629057
View directory record Official record
Conditions
Androgen-insensitive Prostate Cancer
Interventions
MVA-BN-PRO
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Homewood, Alabama • Washington D.C., District of Columbia • Lawrenceville, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Jun 10, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer

NCT04978675
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Fluorine F 18 rhPSMA-7.3, Magnetic Resonance Imaging, Positron Emission Tomography
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Jun 10, 2026, 5:15 AM EDT
Completed Not applicable Interventional

An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer

NCT04318028
View directory record Official record
Conditions
Non-Metastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
7 Tesla Magnetic Resonance Imaging
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Jun 10, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer

NCT00814892
View directory record Official record
Conditions
Prostate Cancer
Interventions
allogeneic tumor cell vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Jun 10, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)

NCT01118741
View directory record Official record
Conditions
Prostate Cancer
Interventions
Disulfiram
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Jun 10, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

NCT00838201
View directory record Official record
Conditions
Cancer, Carcinoma, Castrate-Resistant Prostate Cancer, Prostate Cancer, Tumors
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Huntsville, Alabama • Anaheim, California • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Jun 10, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer

NCT07073794
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Cancer Therapeutic Procedure, Health Care Delivery, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jun 10, 2026, 5:15 AM EDT
Recruiting Early Phase 1 Interventional

An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial

NCT06813898
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium, Positron Emission Tomography
Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Jun 10, 2026, 5:15 AM EDT